Limertinib (diTFA)

• Description:

  Limertinib (ASK120067) diTFA is a potent and orally active inhibitor of EGFRT790M (IC50: 0.3 nM) with selectivity over EGFRWT (IC50: 6.0 nM) . limertinib diTFA is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC) [1].

• Product Name Alternative:

  ASK120067 (diTFA)

• UNSPSC:

  12352005

• Target:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/limertinib-ditfa.html

• Concentration:

  10mM

• Purity:

  98.96

• Solubility:

  DMSO : 175 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=CC(NC2=NC=C(C(NC3=CC4=C(C=CC=C4)C=C3)=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)C=C.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Formula:

  C33H34ClF6N7O6

• Molecular Weight:

  774.11

• References & Citations:

  [1]Tao Zhang, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19 (1) :90.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3